Welcome to the TLDR Biotech newsletter!

Our aim is to be your one-stop source for biotech and pharma updates - all with one daily email.

We’ll likely tweak the exact format and delivery over the next few weeks as we get our feet under us.

So if you have any feedback on what you like (or don’t), we’d love to hear from you!

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

THE GOOD
Approvals & Labels

Toku - FDA breakthrough status for a kidney-disease assessment AI via retinal images
Medical device, AI, kidney disease, diabetes - Read more

Neurocrine lands FDA approval for “sprinkle” Ingrezza formulation
Small molecule, movement disorders - Read more

Boehringer Ingelheim scores FDA approval for Humira biosimilar
mAb, biosimilar, inflammatory disease - Read more

THE GOOD
Clinical Trials

Jacobio ready KRAS lung cancer play with positive data
Small molecule, lung cancer - Read more 

GSK moves up Blenrep regulatory submission, 2024 H2
mAb, multiple myeloma - Read more

THE GOOD
Earnings & Finance

Mustang Bio announces IPO, $4M
Cell therapy, gene therapy - Read more

GSK ups 2024 forecast, partly on strong Arexvy sales
RSV vaccines - Read more

Pfizer beats earnings expectations for Vyndaqel, rare disease drug
Small molecule, transthyretin amyloidosis - Read more

THE GOOD
Fundraises

Novo Holdings pledges €188M towards quantum technologies in Denmark
Ecosystem, company creation, quantum - Read more

PlaqueTec equity financing, $8M
Coronary artery disease, health tech - Read more

SynOx Therapeutics raises “up to” $35M in debt financing
mAb, cancer - Read more

Vitestro $22M (round not disclosed)
Blood draw, AI, health tech - Read more

Vivalyx €5.4M seed round
Organ vitality, organ transplant - Read more

Piction Health $6M seed round
AI, dermatology, virtual health - Read more

Infinitopes £12.8M seed round
Cancer vaccines - Read more

SpinEM Robotics raises €10M, series A2
Health tech, surgery robotics - Read more

Surf Bio’s $1.6M non-dilutive grant, Bill & Melinda Gates Foundation
mAb, drug stability, polymer - Read more

THE GOOD
Marketing

J&J does rebrand on 100-year British anniversary - Read more

THE GOOD
Mergers & Acquisition, Business Development

Akari Therapeutics, Peak Bio outline merger plans
ADC, geographic atrophy - Read more

G1 Therapeutics, Pepper Bio sign licensing agreement
Small molecule, breast cancer - Read more

THE GOOD
Opinions

ARCH Venture Partners and their mega-round ambitions
Fundraises, venture capital - Read more

Pfizer tops physician vaccine trust ranking
Vaccines, physician surveys - Read more

Experts weigh-in on FDA regulating lab tests
Regulatory, laboratory tests - Read more

THE GOOD
Partnerships

Bayer, Evotec partner on precision medicine pact
Cardiology, iPSCs, disease modelling - Read more

Editas Medicine, Bristol Myers Squibb extend cell therapy partnerships
Gene editing, cell therapy, T cell - Read more

Astellas, Poseida Therapeutics CAR-T partnership round 2
CAR-T, allogeneic, solid tumors - Read more

Eli Lilly seeking new partnerships via mountain of obesity-cash - Read more

Beacon Biosignals, Takeda partner on sleep disorder trials
Sleep disorders, medical devices - Read more

Genomics plc, GSK - precision medicine collaboration
Clinical trials, polygenic risk scores - Read more

Lunit, Radiobotics software distribution partnership
AI, medical imaging - Read more

THE GOOD
Research

Mitochondria-targeting drugs may lead to new obesity treatments - Read more

THE GOOD
Strategic Plans

KalVista Pharmaceuticals lays out FY2025 plans
Small molecule, hereditary angioedema - Read more

Pfizer hints vaguely at obesity entrance - Read more

Pfizer sets-up DTC marketplace, follows Eli Lilly’s LillyDirect footsteps - Read more

THE BAD
Earnings & Finances

GE Healthcare Q1 revenue dip due to China sales slowdown
Medical device - Read more

THE BAD
Layoffs

Akili Therapeutics cuts headcount in half
Digital therapeutics - Read more

THE BAD
Opinions

Neuroscience drug development failures, why do they keep happening? - Read more

THE BAD
Pipeline Updates

Pfizer trims pipeline, including a gene therapy
AAV gene therapy - Read more

THE UGLY
Lawsuits

J&J subsidiary courts (pun-intended) $6.4B talc ovarian cancer settlement
Settlement, cancer - Read more

THE UGLY
Politics

How reliant is the US on Chinese out-sourcing? A BIO survey aims to find out
Geopolitics, China - Read more

Don’t look for the WuXi Biologics‘ booth at BIO next month
Geopolitics, CDMO, China - Read more

GSK inhaler costs draws ire of a US Senator
Drug pricing - Read more

You’re all caught up on the latest Pharma & Biotech News!

We want to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send us an email - we want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️